HRP20211989T1 - Stratifikacija genotipa u liječenju i prevenciji dijabetesa - Google Patents
Stratifikacija genotipa u liječenju i prevenciji dijabetesa Download PDFInfo
- Publication number
- HRP20211989T1 HRP20211989T1 HRP20211989TT HRP20211989T HRP20211989T1 HR P20211989 T1 HRP20211989 T1 HR P20211989T1 HR P20211989T T HRP20211989T T HR P20211989TT HR P20211989 T HRP20211989 T HR P20211989T HR P20211989 T1 HRP20211989 T1 HR P20211989T1
- Authority
- HR
- Croatia
- Prior art keywords
- gad
- autoantigen
- individual
- use according
- hla
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title 1
- 238000013517 stratification Methods 0.000 title 1
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 claims 14
- 102000054766 genetic haplotypes Human genes 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150014889 Gad1 gene Proteins 0.000 claims 1
- 108010064885 HLA-DR3 Antigen Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Rehabilitation Therapy (AREA)
- Tropical Medicine & Parasitology (AREA)
Claims (9)
1. GAD autoantigen za upotrebu u postupku za liječenje ili prevenciju autoimunog dijabetesa kod pojedinca, naznačen time što sadrži
- određivanje HLA haplotipa pojedinca; i
- podvrgavanje pojedinca režimu liječenja na temelju navedenog haplotipa,
pri čemu je pojedinac koji ima HLA DR3-DQ2 haplotip podvrgnut tretmanu s najmanje GAD-autoantigenom.
2. GAD autoantigen za upotrebu prema patentnom zahtjevu 1, naznačen time što sadrži
- određivanje HLA haplotipa pojedinca;
- određivanje specifičnosti inicijalno nastalog autoantitijela vezanog uz autoimunu bolest kod pojedinca; i
- podvrgavanje pojedinca režimu liječenja koji se temelji na navedenom haplotipu i specifičnosti navedenog autoantitijela koji se inicijalno pojavljuje.
3. GAD autoantigen za upotrebu prema patentnom zahtjevu 1 naznačen time što je autoimuni dijabetes odabran između dijabetes melitusa tipa 1, dijabetesa 1,5, LADA, LADY, SPIDDM, i PIDM.
4. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što pojedinac je dalje ima GADA prvi.
5. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što se pojedinac koji ima HLA DR3/4-DQ2/8 genotip podvrgava tretmanu s oba GAD autoantigenom i autoantigenom inzulina u istim ili odvojenim formulacijama.
6. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što se pojedinac koji ima HLA-DR3/3-DQ2/2 genotip podvrgava tretmanu s GAD autoantigenom.
7. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-6 naznačen time što primjena GAD-antigena jedna od potkožne, intradermalne ili intra-limfne.
8. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-7 naznačen time što je GAD antigen formuliran sa alaunima.
9. GAD autoantigen za upotrebu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što je GAD autoantigen odabran iz skupine koju čine GAD38, GAD65, i GAD67.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1751094 | 2017-09-08 | ||
| EP18854165.0A EP3678692B1 (en) | 2017-09-08 | 2018-09-10 | Genotype stratification in diabetes treatment and prevention |
| PCT/SE2018/050904 WO2019050465A1 (en) | 2017-09-08 | 2018-09-10 | STRATIFICATION OF GENOTYPE IN THE TREATMENT AND PREVENTION OF DIABETES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211989T1 true HRP20211989T1 (hr) | 2022-03-18 |
Family
ID=65634471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211989TT HRP20211989T1 (hr) | 2017-09-08 | 2018-09-10 | Stratifikacija genotipa u liječenju i prevenciji dijabetesa |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210077587A1 (hr) |
| EP (2) | EP3954384A1 (hr) |
| JP (2) | JP7337780B2 (hr) |
| KR (2) | KR102607713B1 (hr) |
| CN (1) | CN111372602A (hr) |
| CA (1) | CA3074264A1 (hr) |
| CY (1) | CY1124881T1 (hr) |
| DK (1) | DK3678692T3 (hr) |
| EA (1) | EA202090673A1 (hr) |
| ES (1) | ES2902075T3 (hr) |
| HR (1) | HRP20211989T1 (hr) |
| HU (1) | HUE057216T2 (hr) |
| IL (2) | IL312528A (hr) |
| LT (1) | LT3678692T (hr) |
| MX (1) | MX2020002462A (hr) |
| PL (1) | PL3678692T3 (hr) |
| PT (1) | PT3678692T (hr) |
| RS (1) | RS62725B1 (hr) |
| SI (1) | SI3678692T1 (hr) |
| WO (1) | WO2019050465A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839707A (zh) * | 2019-05-14 | 2021-05-25 | 普瑞文森生物有限公司 | 用于预防i型糖尿病的方法和组合物 |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI923719A0 (fi) * | 1992-08-19 | 1992-08-19 | Jaakko Tuomilehto | Detektering av susceptibilitet foer diabetes. |
| EP1755631A2 (en) | 2004-03-03 | 2007-02-28 | Diamyd Medical AB | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
| CN101687019A (zh) * | 2007-04-24 | 2010-03-31 | 迪亚米德治疗股份公司 | 用于治疗自身免疫性疾病和癌症的药物和方法 |
| CN106535926B (zh) * | 2014-06-04 | 2022-02-01 | 戴尔米德医疗公司 | 用于基于抗原的疗法的新型组合物 |
| GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
-
2018
- 2018-09-10 EP EP21195581.0A patent/EP3954384A1/en active Pending
- 2018-09-10 HU HUE18854165A patent/HUE057216T2/hu unknown
- 2018-09-10 HR HRP20211989TT patent/HRP20211989T1/hr unknown
- 2018-09-10 ES ES18854165T patent/ES2902075T3/es active Active
- 2018-09-10 RS RS20211551A patent/RS62725B1/sr unknown
- 2018-09-10 EP EP18854165.0A patent/EP3678692B1/en active Active
- 2018-09-10 IL IL312528A patent/IL312528A/en unknown
- 2018-09-10 MX MX2020002462A patent/MX2020002462A/es unknown
- 2018-09-10 CA CA3074264A patent/CA3074264A1/en active Pending
- 2018-09-10 JP JP2020513715A patent/JP7337780B2/ja active Active
- 2018-09-10 DK DK18854165.0T patent/DK3678692T3/da active
- 2018-09-10 SI SI201830501T patent/SI3678692T1/sl unknown
- 2018-09-10 PT PT188541650T patent/PT3678692T/pt unknown
- 2018-09-10 KR KR1020207009990A patent/KR102607713B1/ko active IP Right Grant
- 2018-09-10 EA EA202090673A patent/EA202090673A1/ru unknown
- 2018-09-10 PL PL18854165T patent/PL3678692T3/pl unknown
- 2018-09-10 IL IL273016A patent/IL273016B2/en unknown
- 2018-09-10 KR KR1020237040525A patent/KR20230167442A/ko not_active Application Discontinuation
- 2018-09-10 US US16/644,461 patent/US20210077587A1/en active Pending
- 2018-09-10 CN CN201880071819.3A patent/CN111372602A/zh active Pending
- 2018-09-10 LT LTEPPCT/SE2018/050904T patent/LT3678692T/lt unknown
- 2018-09-10 WO PCT/SE2018/050904 patent/WO2019050465A1/en active Application Filing
-
2021
- 2021-12-23 CY CY20211101133T patent/CY1124881T1/el unknown
-
2023
- 2023-06-16 JP JP2023099313A patent/JP7551848B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL273016A (en) | 2020-04-30 |
| HUE057216T2 (hu) | 2022-04-28 |
| KR20230167442A (ko) | 2023-12-08 |
| EP3954384A1 (en) | 2022-02-16 |
| DK3678692T3 (da) | 2022-01-03 |
| IL273016B1 (en) | 2024-06-01 |
| KR20200051737A (ko) | 2020-05-13 |
| SI3678692T1 (sl) | 2022-04-29 |
| KR102607713B1 (ko) | 2023-11-29 |
| JP7337780B2 (ja) | 2023-09-04 |
| JP2023116726A (ja) | 2023-08-22 |
| RS62725B1 (sr) | 2022-01-31 |
| WO2019050465A1 (en) | 2019-03-14 |
| CA3074264A1 (en) | 2019-03-14 |
| PL3678692T3 (pl) | 2022-02-28 |
| EP3678692A1 (en) | 2020-07-15 |
| US20210077587A1 (en) | 2021-03-18 |
| IL312528A (en) | 2024-07-01 |
| MX2020002462A (es) | 2020-09-22 |
| JP7551848B2 (ja) | 2024-09-17 |
| EA202090673A1 (ru) | 2020-06-23 |
| JP2020533306A (ja) | 2020-11-19 |
| IL273016B2 (en) | 2024-10-01 |
| LT3678692T (lt) | 2022-01-10 |
| CY1124881T1 (el) | 2022-11-25 |
| CN111372602A (zh) | 2020-07-03 |
| EP3678692A4 (en) | 2021-06-02 |
| EP3678692B1 (en) | 2021-10-20 |
| ES2902075T3 (es) | 2022-03-24 |
| PT3678692T (pt) | 2021-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211989T1 (hr) | Stratifikacija genotipa u liječenju i prevenciji dijabetesa | |
| BR112018002021A2 (pt) | controle de uma nuvem de dispositivos | |
| JP2016536679A5 (hr) | ||
| WO2015169966A3 (en) | Methods for treating inflammatory bowel disease | |
| BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| BR112016002435A2 (pt) | proteínas biomarcadoras da síndrome urêmica hemolítica atípica | |
| IL284219A (en) | Adeno-associated virus (AAV) cell line generation and related processes | |
| BR112019001758A2 (pt) | sistema de enfileiramento de mídia social automatizado | |
| BR112015030435A2 (pt) | temporizadores por processador virtuais para sistemas de processador múltiplo | |
| BR112019007914A2 (pt) | método de controle de iniciação de aplicativo e dispositivo de computador, mídia de armazenamento não-transitória, método de controle de aplicativo, dispositivo de computador e mídia de armazenamento não-transitória | |
| JP2020533306A5 (hr) | ||
| JP2018011926A5 (hr) | ||
| MX2017004742A (es) | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. | |
| WO2016044093A3 (en) | Aeration discs and methods for using same | |
| BR112018010584A2 (pt) | arquitetura de privilégio de modo de gerenciamento de sistema | |
| Khosnenvisan | Handout on Riesz Kernels and Fourier Analysis | |
| EA201792384A1 (ru) | Способ определения наличия конкретных ингредиентов в косметических композициях антиперспирантов и увлажнителей | |
| Kislov | Paleodynamics of large closed lakes as a standard for climate modeling data verification | |
| Yumei et al. | Study on correlation between scene first--aid ability, self efficacy and coping style of community residents. | |
| Al-Issa | The Effectiveness of EMDR Treatment Approach in Treating the Parents, Caregivers and Wives of Young Martyrs With PTSD and Depression Symptoms in Bethlehem District | |
| Tsuzaka | Response to Re: Naftopidil vs silodosin in medical expulsive therapy for ureteral stones: A randomized controlled study in Japanese male patients. | |
| Jakob et al. | A New Framework for Cumulus Parametrization-A CPT in action | |
| Sagredo et al. | Glacial history of Tranquilo glacier (Central Patagonia) since the Last Glacial Maximum through to the present. | |
| Li et al. | Genomic full-length sequence of two HLA-A alleles, A* 30: 01: 01 and A* 30: 04: 01, identified by cloning and sequencing. | |
| Berger | Early signs of ADHD in the preschooler |